BioNTech (BNTX) Fundamental Analysis: Revenue, Earnings & Valuation

2.29 / 10

Underperform

Fundamental assessment rates BioNTech at 2.3/10, classifying it as Underperform. Asset‑MV is negative, while Revenue‑MV and Cash‑MV show modest upside. Inventory turnover is decent, but gross margin is low and cost ratio high, leading to overall weak fundamentals.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score2/3

Weight37.55%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value4.32

Score2/3

Weight-3.69%

1M Return-1.06%

Inventory turnover ratio

Value3.26

Score2/3

Weight-4.30%

1M Return-1.21%

Gross profit margin (%)

Value77.64

Score0/3

Weight-22.39%

1M Return-7.24%

PB-ROE

Value0.01

Score1/3

Weight25.64%

1M Return5.29%

Income tax / Total profit (%)

Value-8.12

Score2/3

Weight4.09%

1M Return1.04%

Fixed assets turnover ratio

Value2.32

Score1/3

Weight-4.27%

1M Return-1.24%

Cost of sales ratio (%)

Value22.36

Score2/3

Weight-14.71%

1M Return-4.42%

Asset-MV

Value-0.55

Score1/3

Weight54.90%

1M Return11.07%

Cash-MV

Value-0.28

Score2/3

Weight27.19%

1M Return5.94%

Is BNTX undervalued or overvalued?

BNTX scores 2.29/10 on fundamentals and holds a Premium valuation at present. Backed by its -5.88% ROE, -39.59% net margin, -17.27 P/E ratio, 1.02 P/B ratio, and -92.38% earnings growth, these metrics solidify its Underperform investment rating.